Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8687630 | NeuroImage: Clinical | 2018 | 22 Pages |
Abstract
Overall at this point in time, the data on AD are most promising towards the eventual use of resting-state fMRI as an imaging biomarker, although there remain issues such as reproducibility of results and a lack of data demonstrating longitudinal changes. Improved methods providing more precise classifications as well as resting-state network changes that are sensitive to disease progression or therapeutic intervention are highly desirable, before routine clinical use could eventually become a reality.
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Christian Hohenfeld, Cornelius J. Werner, Kathrin Reetz,